MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, TNXP had $91,669K increase in cash & cash equivalents over the period. -$61,689K in free cash flow.

Cash Flow Overview

Change in Cash
$91,669K
Free Cash flow
-$61,689K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
Net loss
-77,111
Depreciation and amortization
1,437
Loss on note
-1,159
Loss on extinguishment of debt
-2,092
Bad debt
31
Issuance costs of derivative instruments
1,837
Inventory write-off
1,318
Amortization of debt discount
65
Stock-based compensation
4,228
Accounts receivable
-170
Inventory
-1,362
Prepaid expenses and other
2,159
Accounts payable
3,732
Lease liabilities and rou asset, net
-18
Accrued expenses and other current liabilities
1,663
Net cash used in operating activities
-60,194
Issuance of note
2,012
Purchase of property and equipment
1,495
Net cash used in investing activities
-3,507
Repurchase of common stock
5,949
Payment of term loan
9,650
Proceeds, net of 5,750 and 3,942 expenses, from sale of common stock and warrants
170,986
Net cash provided by financing activities
155,387
Effect of currency rate change on cash
-17
Net increase in cash, cash equivalents and restricted cash
91,669
Cash and cash equivalents at beginning of period
99,680
Cash and cash equivalents at end of period
191,349
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Tonix Pharmaceuticals Holding Corp. (TNXP)

Tonix Pharmaceuticals Holding Corp. (TNXP)